文献速递临床试验与 GCP

继续还是停止?首发精神病抗精神病药物维持与减量/停药对比:HAMLETT实用多中心单盲随机对照试验

To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
PubMed 文献 · Trials · 2020-02-07

HAMLETT研究是一项在荷兰24个站点开展的多中心实用单盲随机对照试验,计划纳入512例16至60岁、首发精神病症状缓解3至6个月的患者,1:1随机分为抗精神病药物维持组(原剂量最大减25%或换用类似剂量范围药物至缓解后至少1年)与逐渐减量至最终停药组,随访4年,评估个人与社会功能、精神病症状严重程度及健康相关生活质量。该研究旨在为首发精神病缓解后最佳治疗时长及何时减药提供证据,并可能识别与安全减量相关的患者特征。

要点

  • 首发精神病缓解后继续抗精神病药物与减量/停药对功能结局的对比尚存争议。
  • HAMLETT计划纳入512例缓解3至6个月的首发精神病患者,1:1随机分组。
  • 主要评估个人与社会功能、症状严重程度及健康相关生活质量,随访4年。

核心结论

  • HAMLETT研究将为首发精神病缓解后抗精神病药物最佳治疗时长及减药时机提供证据。
  • 该研究可能识别与安全减量、复发风险最低相关的患者特征。

研究设计与样本

  • 多中心实用单盲随机对照试验,两种平行条件按1:1随机分组。
  • 计划纳入512例16至60岁、首发精神病症状缓解3至6个月且精神病与严重或危及生命的自伤或暴力无关的患者。
  • 招募在荷兰24个站点进行,测量在基线、基线后3个月和6个月以及4年随访期间每年进行。

关键数值与推荐

  • 维持组:继续抗精神病药物至缓解后至少1年,原剂量允许最大减25%,或换用类似剂量范围的其他抗精神病药物。
  • 减量组:按逐渐减量计划减至最终停用抗精神病药物;若出现复发迹象可重新增加剂量。
  • 多数指南推荐首发精神病症状缓解后继续抗精神病药物治疗至少1年。

临床怎么用

  • 为临床医生和患者讨论首发精神病缓解后最佳治疗时长及何时减药提供随机对照证据。
  • 减量组出现复发迹象时可重新增加药物剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotic medication is effective for symptomatic treatment in schizophrenia-spectrum disorders. After symptom remission, continuation of antipsychotic treatment is associated with lower relapse rates and lower symptom severity compared to dose reduction/discontinuation. Therefore, most guidelines recommend continuation of treatment with antipsychotic medication for at least 1 year. Recently, however, these guidelines have been questioned as one study has shown that more patients achieved long-term functional remission in an early discontinuation condition-a finding that was not replicated in another recently published long-term study. METHODS/DESIGN: The HAMLETT (Handling Antipsychotic Medication Long-term Evaluation of Targeted Treatment) study is a multicenter pragmatic single-blind randomized controlled trial in two parallel conditions (1:1) investigating the effects of continuation versus dose-reduction/discontinuation of antipsychotic medication after remission of a first episode of psychosis (FEP) on personal and social functioning, psychotic symptom severity, and health-related quality of life. In total 512 participants will be included, aged between 16 and 60 years, in symptomatic remission from a FEP for 3-6 months, and for whom psychosis was not associated with severe or life-threatening self-harm or violence. Recruitment will take place at 24 Dutch sites. Patients are randomized (1:1) to: continuation of antipsychotic medication until at least 1 year after remission (original dose allowing a maximum reduction of 25%, or another antipsychotic drug in similar dose range); or gradual dose reduction till eventual discontinuation of antipsychotics according to a tapering schedule. If signs of relapse occur in this arm, medication dose can be increased again. Measurements are conducted at baseline, at 3, and 6 months post-baseline, and yearly during a follow-up period of 4 years. DISCUSSION: The HAMLETT study will offer evidence to guide patients and clinicians regarding questions concerning optimal treatment duration and when to taper off medication after remission of a FEP. Moreover, it may provide patient characteristics associated with safe dose reduction with a minimal risk of relapse. TRIAL STATUS: Protocol version 1.3, October 2018. The study is active and currently recruiting patients (since September 2017), with the first 200 participants by the end of 2019. We anticipate completing recruitment in 2022 and final assessments (including follow-up 3.5 years after phase one) in 2026. TRIAL REGISTRATION: European Clinical Trials Database, EudraCT number 2017-002406-12. Registered 7 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020. PMID: 32033579. doi:10.1186/s13063-019-3822-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。